Hemodynamics, fluids & transfusion
Cardiogenic shock in patients with active onco-hematological malignancies: A multicenter retrospective study
Authors' conclusion
The prognosis for OH patients with CS in the ICU is poor, with epinephrine use associated with worse outcomes.
Study context
- Population
- Patients with active onco-hematological malignancies and cardiogenic shock in 22 intensive care units (ICUs) (2010–2021)
- Participants
- 214 patients · 22 ICUs
- Exposure
- Onco-hematological (OH) patients with cardiogenic shock (CS) vs control CS patients
- OHn = 214
- Outcome
- Risk factors for 30-day mortality
- Follow-up
- 30 days
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
30-day survival and risk factors for 30-day mortality
- 30-day survival rate
- 44.8 %
- Previous cardiomyopathy, associated with 30-day mortality (OR)
- 1.61
- AKI, associated with 30-day mortality (OR)
- 1.62
- Lactate levels, associated with 30-day mortality (OR per 1 mmol/L)
- 1.08
- PE, associated with 30-day mortality (OR)
- 3.04
- Invasive mechanical ventilation, associated with 30-day mortality (OR)
- 3.48
- Epinephrine use, associated with 30-day mortality (OR)
- 2.09
Observational data: associations, not effects.
Further findings
| Outcome | HR |
|---|---|
| 30-day mortality, OH malignancy vs control · significantly associated | 2.54 |
1-year survival and LVEF among ICU survivors
%
- Alive at 1 year among ICU survivors
- 54
- Median left ventricular ejection fraction
- 52
Original publication
Cardiogenic shock in patients with active onco-hematological malignancies: A multicenter retrospective study. J Crit Care. Published 22 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →